Premium
THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B‐CELL LYMPHOMAS
Author(s) -
Villasboas J.C.,
Reeder C.B.,
Tun H.W.,
Bartlett N.L.,
Sharon E.,
LaPlant B.,
Adjei A.,
Ansell S.M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.38_2629
Subject(s) - nivolumab , medicine , lymphoma , oncology , aggressive lymphoma , cancer research , immunology , cancer , immunotherapy , rituximab